NASDAQ:TBIOTranslate Bio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Translate Bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.44 +1.46 (+7.69 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range$18.71Now: $20.44▼$20.8650-Day Range$8.33MA: $12.63▼$19.9252-Week Range$6.80Now: $20.44▼$21.95Volume646,453 shsAverage Volume952,491 shsMarket Capitalization$1.29 billionP/E RatioN/ADividend YieldN/ABeta0.25 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingTranslate Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.75, Translate Bio has a potential upside of 1.5% from its current price of $20.44.Amount of Analyst CoverageTranslate Bio has received no research coverage in the past 90 days. Previous Next 1.6 Community Rank Outperform VotesTranslate Bio has received 90 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTranslate Bio has received 183 “underperform” votes. (Add your “underperform” vote.)Community SentimentTranslate Bio has received 67.03% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Translate Bio and other stocks. Vote “Outperform” if you believe TBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTranslate Bio does not currently pay a dividend.Dividend GrowthTranslate Bio does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Translate Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 15.40% of the stock of Translate Bio is held by insiders.Percentage Held by Institutions82.63% of the stock of Translate Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Translate Bio are expected to decrease in the coming year, from ($1.70) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Translate Bio is -12.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Translate Bio is -12.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTranslate Bio has a P/B Ratio of 9.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.82 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TBIO Previous Symbol CUSIPN/A CIKN/A Webwww.translate.bio Phone617-945-7361Debt Debt-to-Equity Ratio0.08 Current Ratio4.12 Quick Ratio4.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.80 million Price / Sales164.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book9.00Profitability EPS (Most Recent Fiscal Year)($1.84) Net Income$-113,290,000.00 Net Margins-859.22% Return on Equity-63.61% Return on Assets-29.18%Miscellaneous Employees81 Outstanding Shares62,910,000Market Cap$1.29 billion Next Earnings Date7/29/2020 (Estimated) OptionableNot Optionable NASDAQ:TBIO Rates by TradingView Receive TBIO News and Ratings via Email Sign-up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter. Translate Bio (NASDAQ:TBIO) Frequently Asked Questions How has Translate Bio's stock been impacted by COVID-19 (Coronavirus)? Translate Bio's stock was trading at $7.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TBIO shares have increased by 175.1% and is now trading at $20.44. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Translate Bio? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Translate Bio. When is Translate Bio's next earnings date? Translate Bio is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Translate Bio. How were Translate Bio's earnings last quarter? Translate Bio Inc (NASDAQ:TBIO) posted its earnings results on Thursday, March, 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.12. The business had revenue of $3.89 million for the quarter, compared to analyst estimates of $3.06 million. Translate Bio had a negative net margin of 859.22% and a negative return on equity of 63.61%. View Translate Bio's earnings history. What price target have analysts set for TBIO? 4 brokerages have issued twelve-month price objectives for Translate Bio's shares. Their forecasts range from $17.00 to $25.00. On average, they anticipate Translate Bio's stock price to reach $20.75 in the next year. This suggests a possible upside of 1.5% from the stock's current price. View analysts' price targets for Translate Bio. What are Wall Street analysts saying about Translate Bio stock? Here are some recent quotes from research analysts about Translate Bio stock: 1. According to Zacks Investment Research, "Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States. " (5/15/2020) 2. HC Wainwright analysts commented, "Valuation and risks to achievement of target price. Our price target of $21/share is based on an equally-weighted composite of: (a) $16.9/share, as a 35x multiple of taxed and diluted $4.33 discounted back to FY19 at 18% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $25.6/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/1/2019) Has Translate Bio been receiving favorable news coverage? News headlines about TBIO stock have been trending extremely negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Translate Bio earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutTranslate Bio. Are investors shorting Translate Bio? Translate Bio saw a drop in short interest in May. As of May 15th, there was short interest totaling 3,680,000 shares, a drop of 32.8% from the April 30th total of 5,480,000 shares. Based on an average trading volume of 477,600 shares, the short-interest ratio is currently 7.7 days. Currently, 8.8% of the shares of the stock are short sold. View Translate Bio's Current Options Chain. Who are some of Translate Bio's key competitors? Some companies that are related to Translate Bio include Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), bluebird bio (BLUE), Halozyme Therapeutics (HALO), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT) and Adverum Biotechnologies (ADVM). View all competitors. What other stocks do shareholders of Translate Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Regeneron Pharmaceuticals (REGN), Johnson & Johnson (JNJ), Moderna (MRNA), NVIDIA (NVDA), AbbVie (ABBV), Tesla (TSLA) and Carnival (CCL). Who are Translate Bio's key executives? Translate Bio's management team includes the following people: Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 50)Dr. Michael W. Heartlein, Chief Technology Officer (Age 60)Mr. John R. Schroer C.F.A., CFA, CFO & Treasurer (Age 54)Dr. Richard Wooster, Chief Scientific Officer (Age 59)Mr. Paul D. Burgess J.D., Chief Legal Officer & Corp. Sec. (Age 45) When did Translate Bio IPO? (TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO. What is Translate Bio's stock symbol? Translate Bio trades on the NASDAQ under the ticker symbol "TBIO." Who are Translate Bio's major shareholders? Translate Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.27%), Federated Hermes Inc. (3.64%), Camber Capital Management LP (2.81%), Rock Springs Capital Management LP (1.31%), State Street Corp (1.13%) and Geode Capital Management LLC (0.93%). Company insiders that own Translate Bio stock include Brian M Jr Gallagher and Mrl Ventures Fund Llc. View institutional ownership trends for Translate Bio. Which institutional investors are selling Translate Bio stock? TBIO stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Morgan Stanley, UBS Group AG, Ensign Peak Advisors Inc, New York State Common Retirement Fund, Virtus ETF Advisers LLC, Legal & General Group Plc, and Victory Capital Management Inc.. View insider buying and selling activity for Translate Bio. Which institutional investors are buying Translate Bio stock? TBIO stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Federated Hermes Inc., State Street Corp, JPMorgan Chase & Co., Invesco Ltd., Geode Capital Management LLC, BlackRock Inc., and ClariVest Asset Management LLC. Company insiders that have bought Translate Bio stock in the last two years include Brian M Jr Gallagher, and Mrl Ventures Fund Llc. View insider buying and selling activity for Translate Bio. How do I buy shares of Translate Bio? Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Translate Bio's stock price today? One share of TBIO stock can currently be purchased for approximately $20.44. How big of a company is Translate Bio? Translate Bio has a market capitalization of $1.29 billion and generates $7.80 million in revenue each year. The company earns $-113,290,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Translate Bio employs 81 workers across the globe. What is Translate Bio's official website? The official website for Translate Bio is www.translate.bio. How can I contact Translate Bio? Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361. This page was last updated on 5/24/2020 by MarketBeat.com Staff
